CU-10401

CU-10401 is a topical small molecule drug candidate being developed by Cutia Therapeutics for the treatment of psoriasis. As of early 2024, the compound is in the preclinical or IND-enabling stage of development. Cutia Therapeutics, a dermatology-focused biopharmaceutical company based in China, is developing CU-10401 as a potential non-steroidal therapy for plaque psoriasis. While the specific molecular target of CU-10401 has not been publicly disclosed in the sponsor's primary pipeline documents, it is part of a broader portfolio of topical dermatological treatments that includes other small molecules such as roflumilast (CU-10101) and JAK inhibitors (CU-10301). The program aims to provide a localized treatment option for psoriasis patients with a favorable safety profile.